EDITOR
Neil Love, MD

MEET THE PROFESSORS CASE DISCUSSIONS

Case 1: A 62-year-old man who presented with a PSA of five ng/mL underwent radical prostatectomy and had a pathologic Stage T2B, Gleason 7 (4 + 3) prostate cancer with 40 to 50 percent involvement of the gland and a focal positive margin at the anterior edge of the apex (from the practice of Alan M Nieder, MD)
- Select publications

Case 2: A 53-year-old man with a history of colon cancer whose PSA level rose from 3.8 to 7.9 ng/mL in one year, with pathologic T3 Gleason 4 + 5 prostate cancer with extracapsular extension, negative nodes, seminal vesicles and margins after nerve-sparing prostatectomy (from the practice of Michael A Simon, MD)
- Select publications

Case 3: A 50-year-old man with an abnormal DRE (slightly indurated left lobe), a PSA level of 0.2 ng/mL with 1/12 positive cores (one percent) and Gleason 6 prostate cancer (from the practice of Richard Davi, MD)
- Select publications

Case 4: An 84-year-old man who underwent external beam radiation therapy 10 years ago for Gleason 7 prostate cancer and was treated with an LHRH agonist and then MAB therapy for PSA recurrences. Currently, he has bone metastases, with a PSA of 50 ng/mL, and he is receiving docetaxel and prednisone for bone pain (from the practice of Dr Nieder)
- Select publications

Case 5: A 71-year-old man with a PSA rising from five to 18.1 ng/mL in the year prior to diagnosis of Gleason 6-7 prostate cancer, with 9/13 positive cores (85 percent) and DRE abnormal bilaterally. Bone and CT scans were negative (from the practice of Benjamin M Tripp, MD)
- Select publications

INTERVIEWS

Judd W Moul, MD
Professor and Chief
Division of Urologic Surgery
Duke University Medical Center
Durham, North Carolina
- Select publications

Daniel P Petrylak, MD
Associate Professor of Medicine
Director, Genitourinary Oncology Program
Columbia Presbyterian Medical Center
New York, New York
- Select publications

A CME Audio Series and Activity

Faculty disclosure

Editor's Office